



NASPCC Webinar Series Presents:
“Epigenetic Control of Cancer Immunity”

With Leigh Ellis, PhD

Wednesday, January 12, 2022 from

7:00 pm – 8:00 pm EASTERN / 4:00 pm – 5:00 pm PACIFIC

To register for this event, please visit the NASPCC website at

www.NASPCC.org



Dr. Leigh Ellis, Scientific Director of the Center for Urologic Research Excellence and Associate Professor, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center

The Ellis laboratory’s focus is the discovery of how a prostate cancer cell controls the expression of genes (epigenetics) to drive metastasis and resistance to current therapies. Their work has demonstrated how the epigenetic regulator, EZH2, controls prostate cell fidelity and evasion of immune detection, and has shown that inhibition of EZH2 resulted in reprogramming both the prostate tumor and its tumor microenvironment to re-sensitize to androgen deprivation therapy and check-point immunotherapy.

AMGEN

2nd in a series of 6 Immuno-Oncology webinars sponsored by AMGEN